MiMedx To Present At 2014 Canaccord Genuity Musculoskeletal Conference


Mar 04, 2014, 16:52 ET from MiMedx Group, Inc.

MARIETTA, Ga., March 4, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer  of  patent  protected  regenerative  biomaterials  and bioimplants processed from human amniotic membrane, announced today that it will present at the 2014 Canaccord|Genuity Musculoskeletal Conference in New Orleans, Louisiana.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Tuesday, March 11th at 10:00am CDT/11:00am EDT, at the Sheraton New Orleans. A webcast of this presentation will be available on the Company's website, www.mimedx.com.

MiMedx will also be exhibiting the Company's human amniotic membrane allograft tissue technologies at the 2014 Annual Meeting of the American Association of Orthopaedic Surgeons. Throughout the conference, MiMedx plans to sponsor various meetings with physicians, scientists and investors to discuss and demonstrate the benefits and potential of our PURION® Processed allografts.  MiMedx Group will be located in Booth 1173 at the New Orleans Morial Convention Center. 

About MiMedx MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 200,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

SOURCE MiMedx Group, Inc.